Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > Bloom Burton update $0.80 tp

<< Previous

Bullboard Posts

Next >>

Comment by wizzdumbon Feb 16, 2024 9:06am

115 Views

Post# 35883815

RE:RE:RE:RE:RE:Bloom Burton update $0.80 tp

Yes, I'd say it's a reasonable but conservative analysis of their core business but key is it does not factor in Kinlytic. So basically today you're getting the core business at half of conservative valuation and an option on Kinlytic, a massive opportunity that one the worlds largest healthcare private equity firms is spending $50M on pre revenue and that has little to no clinical risks, for free.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?